GET DAILY SIGNALSCVS Health (CVS): Why Analysts See +27% Upside to $115 Target
Key Takeaways
- The central $115 target is the rounded average of current analyst price targets — roughly $115.48 across about 27 analysts tracked by S&P Global.
- With CVS Health Corporation (CVS) trading near $90.25, reaching $115 implies upside of about 27%, a substantial move rather than an incremental one.
- Individual targets span a wide band, roughly $103 to $145, reflecting genuine disagreement about how far the multi-year recovery can run.
- The bull case centers on consecutive earnings beats, raised full-year guidance, and improving Aetna Medicare Advantage (MA) medical costs.
- The principal risks are managed-care underwriting pressure, pharmacy benefit manager (PBM) regulation, retail pharmacy competition, and elevated debt.
- Readers can track CVS Health's Major News, Today's Price Move, Forecast, and Earnings on Tickeron's dedicated pages for the latest detail.
- Explore Trending AI Robots to see how AI-driven models are monitoring CVS and other names in real time.
Analyst Price Targets and Consensus View
CVS Health is a stock, not an exchange-traded fund, so the central target is built from analyst price targets. S&P Global data collected across roughly 27 analysts places the average 12-month price target near $115.48, which rounds to a clean $115. The range is unusually wide — approximately $103 on the low end to $145 on the high end — which underscores how differently analysts frame the company's recovery.
Recent individual calls illustrate the spread. Bank of America reiterated a Buy with a $110 target in mid-October 2026, Leerink Partners lowered its target to $112 (from $119) while keeping an Outperform rating, RBC Capital stood at $113, and Bernstein moved to $112. On the more constructive side, UBS and JPMorgan each carried $118 targets, while Wells Fargo held a high-profile $123 target. At the cautious end, HSBC maintained a Hold with a $103 target, and Cantor Fitzgerald reiterated a Neutral stance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The consensus skews decisively positive — often described as Strong Buy or Moderate Buy — with a large majority of analysts in the bullish camp and only a handful of holds. There are essentially no sell ratings, yet the gap between the lowest and highest targets shows that analysts disagree on the pace and durability of margin recovery rather than on the company's direction.
Current Market Position and Path Toward the Target
The stock closed near $90.25 in late October 2026, inside a 52-week range of roughly $69.51 to $110.68. Reaching $115 requires a gain of about 27%, a substantial move that would take the shares above their prior 52-week high. It would not be a record-breaking run, but it would require sustained earnings delivery and a meaningful re-rating of sentiment.
The path would likely run through continued improvement in the Health Care Benefits segment, where Aetna's medical benefit ratio (the share of premiums spent on care) has been normalizing, and through steadier contribution from the pharmacy and Caremark PBM businesses. With a market capitalization near $115 billion, a trailing P/E (price-to-earnings ratio) in the mid-20s, and a dividend yield near 3%, the stock remains a value-and-income story that bulls argue has yet to fully price in earnings recovery.
What Could Support a Move Toward the Target
The most important support is earnings momentum. CVS has beaten estimates in recent quarters — one report showed EPS (earnings per share) of $2.58 against a roughly $1.87 consensus — and management has raised full-year guidance multiple times. Full-year 2026 guidance sits around $7.90 to $8.10 per share, with analysts near the middle of that range.
Beyond the numbers, improving Medicare Advantage star ratings and the company's redesigned MA benefits give analysts visibility into durable margin expansion. A broader rotation into healthcare stocks, strong free cash flow, and cost-control progress across the insurance and pharmacy segments are also cited as tailwinds. If quarterly results continue to beat and guidance keeps rising, analysts could lift targets further, narrowing the distance to $115.
What Could Prevent the Target From Being Reached
The clearest obstacle is the managed-care underwriting cycle. Goldman Sachs and others have described the current downturn as among the most significant in more than 15 years, and a slower-than-expected recovery in Medicaid and ACA exchange plans could keep medical costs elevated. Regulatory risk also looms — proposed changes to PBM practices, pharmacy reimbursement, and Affordable Care Act subsidies could pressure revenue and margins.
Valuation is a secondary concern. Even after the recovery, CVS trades at a premium to some healthcare peers, and any guidance cut or renewed spike in medical costs could compress the multiple. Persistent competition from rivals such as Amazon and Walmart in retail pharmacy, along with a leveraged balance sheet, adds further downside risk that could keep the shares below even the lowest analyst targets.
Technical Levels and Market Structure
Technically, the stock is in a longer-term recovery after a deep drawdown, but it remains below the $110.68 52-week high, which now acts as the nearest major resistance level ahead of the $115 target. The $100 psychological level is the next obvious hurdle. On the downside, support has repeatedly formed in the $86 to $90 zone, with the 52-week low near $69.51 representing a deeper floor. A sustained move above the prior high would signal a structural breakout, while repeated failures near $100 could keep the range intact.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a forward research horizon of about 12 months, though firms vary, and the company's own multi-year margin story extends beyond that window. The next key event is CVS Health's quarterly earnings, scheduled for early November 2026, where investors will watch medical benefit ratio trends, Medicare Advantage enrollment, full-year guidance, and any commentary on 2027. Beyond earnings, monitor analyst target revisions, ACA subsidy and PBM regulatory developments, healthcare sector rotation, and the stock's behavior around the $100 and $110.68 levels.
Using AI Signals to Track Developments
I often rely on Tickeron's AI Daily Buy/Sell Signals to stay on top of shifting trends in names like this. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals drawn from market conditions and technical behavior. It serves as a practical complement to fundamental work, helping surface opportunities and track evolving positions without replacing core research.
Final Assessment
The $115 central target — the rounded average of roughly 27 analyst price targets — sits about 27% above the recent price near $90.25. It is achievable only if the company's earnings recovery, led by Aetna's margin normalization, continues at its current pace and if regulatory and underwriting headwinds do not resurface. The wide $103-to-$145 analyst range signals real uncertainty, and the fact that the shares trade below even the lowest named target shows investors remain more cautious than analysts. The next earnings report, margin trends, and any analyst revisions will be the clearest indicators of whether the gap toward $115 begins to close. From what I see, this remains a story worth following closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CVS in upward trend: 10-day moving average broke above 50-day moving average on October 23, 2026
The 10-day moving average for CVS crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for CVS just turned positive on October 06, 2026. Looking at past instances where CVS's MACD turned positive, the stock continued to rise in 33 of 50 cases over the following month. The odds of a continued upward trend are 66%.
Following a +2.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVS advanced for three days, in 228 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 155 of 253 cases where CVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for CVS moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 26 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVS as a result. In 55 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.
CVS moved below its 50-day moving average on October 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
CVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CVS's P/B Ratio (1.448) is slightly lower than the industry average of (3.380). P/E Ratio (23.626) is within average values for comparable stocks, (124.266). CVS's Projected Growth (PEG Ratio) (0.206) is slightly lower than the industry average of (0.786). CVS has a moderately high Dividend Yield (0.029) as compared to the industry average of (0.009). P/S Ratio (0.283) is also within normal values, averaging (0.569).
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating fairly steady price growth. CVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 74 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an integrated pharmacy health care provider
Industry ManagedHealthCare
Advertisement